Oxford Gene Technology, a provider of innovative clinical genetics and diagnostic solutions, has entered into an exclusive licensing agreement with Inven2, the technology transfer office at Oslo University Hospital and University of Oslo, for 12 colorectal cancer tissue biomarkers, according to a news release.
The license allows OGT to commercialize tests developed using the biomarkers and to sublicense the markets to other parties. The biomarkers were developed in the department of Cancer Prevention at the Norwegian Radium Hospital, a part of the Oslo University Hospital. OGT has validated the results from tests showing sensitivity of 93 percent and specificity of 90 percent when using tissue biopsies.
Related Articles on Colon Cancer:
Global Markets Direct Releases Colon Cancer Pipeline Report
Dr. Patricia Raymond Produces Music Video to Raise Colonoscopy Screening Awareness Among African-American Community
Colon Cancer Alliance Praises FDA's Biosimilars Guidance
The license allows OGT to commercialize tests developed using the biomarkers and to sublicense the markets to other parties. The biomarkers were developed in the department of Cancer Prevention at the Norwegian Radium Hospital, a part of the Oslo University Hospital. OGT has validated the results from tests showing sensitivity of 93 percent and specificity of 90 percent when using tissue biopsies.
Related Articles on Colon Cancer:
Global Markets Direct Releases Colon Cancer Pipeline Report
Dr. Patricia Raymond Produces Music Video to Raise Colonoscopy Screening Awareness Among African-American Community
Colon Cancer Alliance Praises FDA's Biosimilars Guidance